

India-US joint research grants on Vaccine Adjuvant Development

12 August 2019 | News

Under the aegis of Indo US Vaccine Action Programme (VAP)



Vaccine research and development is a priority area in the Department of Biotechnology (DBT) supported through an important mission called the National Biopharma Mission (NBM).

NBM is an Industry-Academia Collaborative Mission of Department of Biotechnology for Accelerating Early Development for Biopharmaceuticals; being implemented by Biotechnology Industry Research Assistance Council (BIRAC), a Public Sector Undertaking of DBT aiming to create an ecosystem for innovative indigenous product development by researchers, startups and SMEs (Small and Medium Enterprises) to make Indian biotech industry globally competitive.

Considering vaccine adjuvant research as an important area for vaccine development Department of Biotechnology in collaboration with National Institute of Allergy and Infectious Diseases (NIAID)- National Institutes of Health (NIH) invites proposals for the discovery, development, and/or preclinical testing of vaccine adjuvants under the aegis of Indo US Vaccine Action Programme (VAP).

VAP is one of the oldest bilateral programmes that supports a wide range of collaborative activities related to immunology, infectious disease biology and vaccine research.

The aim of this call is to strengthen vaccine adjuvant research in India. This joint DBT & NBM-BIRAC call will leverage the funding expertise of both the organizations.